BIIB News Alert Biogen Idec Inc (BIIB) 333.40 09/25/2014 20:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biogen Idec Inc (BIIB) 333.40 $BIIB

Technology Stocks Slide But Other Sectors Hold Up Better
at Investor's Business Daily - 2 hrs 44 mins ago
A harsh sell-off in the market Thursday did not spare many stocks in Your Weekly Review. Nearly every stock on the screen closed lower, and the selling affected certain sectors more than others. However, few leaders triggered outright sell signals....

Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014
Business Wire - Thu Sep 25, 4:34PM CDT
Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report third quarter 2014 financial results on Wednesday, October 22, 2014, before the financial markets open.

Stocks Get Hit Hard; GoPro, Skechers Buck Weakness
at Investor's Business Daily - Thu Sep 25, 3:23PM CDT
Stocks suffered their biggest losses in nearly two months Thursday amid mixed data on weekly jobless claims and durable goods. Hurt by a near 4% drop in Apple (AAPL), the Nasdaq tumbled 1.9%. The S&P 500 lost 1.6%. Both indexes breached support at...

Wave Of Selling Hits Stocks; IPO CyberArk Extends Gains
at Investor's Business Daily - Thu Sep 25, 12:31PM CDT
Buyers were in short supply in early-afternoon trading Thursday as another wave of institutional selling hit the Nasdaq. The tech-laden index slumped 1.8%, weighed down by weakness in Apple (AAPL). The Dow Jones industrial average and S&P 500 lost...

Apple Fuels Tech Sell-Off; Valeant Bucks The Trend
at Investor's Business Daily - Thu Sep 25, 10:34AM CDT
Major averages were sharply lower two hours into Thursday's session. The Nasdaq slumped 1.7% as Apple cast a pall on the tech sector. The Dow Jones industrial average and S&P 500 lost 1.2% each, and small caps took another hit as the Russell 2000...

Stock Market News for September 25, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 9:10AM CDT
Markets rebounded on Wednesday after taking losses in three straight sessions

Jim Cramer's 'Mad Money' Recap: Why You Can't Get Too Negative in This Market
at The Street - Wed Sep 24, 7:24PM CDT
Investors always need to be prepared for when common sense returns to the market, Cramer says.

Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 4.23%
Comtex SmarTrend(R) - Wed Sep 24, 3:46PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $333.11 to a high of $347.75. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $334.95 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 4.23% Gain
Comtex SmarTrend(R) - Wed Sep 24, 3:46PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $333.11 to a high of $347.75. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $334.95 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Stocks End Skid; Vertex, Alexion Lead Biotech Rebound
at Investor's Business Daily - Wed Sep 24, 3:16PM CDT
The major averages rose Wednesday, erasing most of the week's losses, aided by dovish comments from a top Federal Reserve official. The Nasdaq rose 1%, the Dow Jones industrial average 0.9% and the S&P 500 0.8%. Volume was mixed, rising 6% on the...

Stocks Up In Afternoon; Hasbro Jumps On Disney Deal
at Investor's Business Daily - Wed Sep 24, 2:05PM CDT
The major averages were hitting fresh intraday highs in late afternoon trading Wednesday, spurred by dovish comments from a top Federal Reserve policymaker. The Nasdaq and the Dow Jones industrial average each added 0.9%, while the S&P 500 picked up...

Acorda To Buy Civitas, Gains Parkinson's Disease Drug
at Investor's Business Daily - Wed Sep 24, 12:27PM CDT
Acorda Therapeutics (ACOR) stock popped after the biotechnology company agreed to buy privately held Civitas Therapeutics for $525 million, gaining access to drugs in late development used to treat Parkinson's disease. Acorda obtained global rights...

Stocks Hold Solid Gains; CyberArk Soars In Debut
at Investor's Business Daily - Wed Sep 24, 12:20PM CDT
Major averages held solid gains in early afternoon trading Wednesday. The Nasdaq added 0.6%, the Dow Jones industrial average rose 0.5% and the S&P 500 picked up 0.4%. NYSE volume was tracking slightly higher than Wednesday. Nasdaq volume was...

Results of Clinical Trials, New Drug Applications, Leadership Appointments, and Scheduled Earnings - Research Reports on Biogen, Salix, Express Scripts, Stryker and Shire
PR Newswire - Tue Sep 23, 8:25AM CDT
Today, Analysts Review released its research reports regarding Biogen Idec Inc. (NASDAQ: BIIB), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Express Scripts Holding Company (NASDAQ: ESRX), Stryker Corporation (NYSE: SYK) and Shire plc. (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6674-100free.

Biopharmaceutical and Vaccine Production Markets to 2018
M2 - Tue Sep 23, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h2pzn6/biopharmaceutical) has announced the addition of the "Biopharmaceutical and Vaccine Production Markets" report to their offering. Though biotechnology has created many new therapies and vaccines - including products to treat cancer, diabetes, HIV/AIDS and autoimmune disorders - there are still huge challenges during the final stages of clinical drug testing for new biopharmaceuticals, as manufacturers decide when and how to risk production capital to upscale while anticipating FDA or EMA approval. During the past five years, estimates for biopharmaceuticals have varied widely as analysts and producers have juggled the promise of new drugs with the technological and financial risks of manufacturing them efficiently. Biopharmaceutical and Vaccine Production Markets examines the total biopharmaceutical manufacturing market, including in its estimates all costs related to biopharmaceutical and vaccine production. It includes the following useful information for business planning: - Market Forecasts and Estimates of Biopharmaceutical Manufacturing Costs - Vaccine Production Estimates - Trend Discussion - Production Methods - The Competitive Environment, including Contract Manufacturing and Outsourcing - Regulation of the Market - Company Profiles The report contains production segmentations for the mammalian cell, microbial cell, monoclonal antibody, other recombinant protein, vaccine, and insulin manufacturing markets, with forecasts to 2018. The current competitive environment is noted, listing selected biopharmaceutical contract manufacturers, selected top-selling biopharmaceuticals, selected Asian biomanufacturing contract manufacturing organizations (CMOs), the top 10 biopharma companies based on 2012 biopharma revenues, and the top manufacturers by global biopharmaceutical manufacturing capacity. Report profiles of major contract manufacturers: - Lonza AG - Boehringer Ingelheim GmbH - FUJIFILM Diosynth Biotechnologies - Sandoz - Royal DSM - Rentschler Biotechnologie - Celonic - BIOMEVA GmbH - ProBioGen AG - Baxter BioPharma Solutions/Baxter Bioscience Major biologics firms : - Amgen - Genentech/Roche - AbbVie Inc. (Abbott) - Biogen Idec - Regeneron Pharmaceuticals - Alexion Pharmaceuticals - Crucell /Johnson & Johnson - GlaxoSmithKline - Merck & Co. Inc - Novartis - Pfizer - Sanofi Pasteur Other contract manufacturers profiled - AAIPharma - A-Bio Pharma Pte Ltd. - ABL, Inc. - Affinity Life Sciences, Inc. - Ajinomoto Aminoscience, LLC - Alliance Medical Products, Inc. - Alpha Biologics - Biotecnol - Boston Mountain Biotech - Glycobia - Sutro Biopharma Key Topics Covered: - Executive Summary - Commercial Production - Forecasts - Regulation - Competitive Environment - Patents - Geography - Profiles For more information visit http://www.researchandmarkets.com/research/h2...maceutical

Biogen Idec Named Global Biotechnology Industry Leader on Dow Jones Sustainability World Index
Business Wire - Tue Sep 23, 7:00AM CDT
Biogen Idec (NASDAQ:BIIB) has been named the biotechnology industry leader on the Dow Jones Sustainability World Index (DJSI World). The company also was named to the Dow Jones Sustainability Index (DJSI) North America for the fifth consecutive year, one of only two biotech companies included. In September 2013, Biogen Idec became the first U.S.-based biotechnology company to be named to DJSI World.

Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy
Business Wire - Tue Sep 23, 6:00AM CDT
Biogen Idec (NASDAQ:BIIB) today announced that Olivier Danos, Ph.D., has joined the company as senior vice president, Gene Therapy. Dr. Danos reports directly to Douglas Williams, Ph.D., executive vice president, Research and Development, and is a member of Biogen Idec's Senior Research and Development Leadership Team.

Most Big Cap 20 Stocks Near Entries, But Risks Exist
at Investor's Business Daily - Mon Sep 22, 6:05PM CDT
Most of the Big Cap 20 stocks are in buy ranges or forming bases. That's an unusually good trend that affords investors plenty of opportunities to deploy capital. But a sluggish market poses risks for any new purchases. For those willing to risk...

Isis Pharmaceuticals Up on $4M Milestone Payment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:40PM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a $4 million milestone payment from Achaogen (AKAO), following the initiation of a phase III study on plazomicin.

Gilead's (GILD) Zydelig Gets EU Clearance for Blood Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:20PM CDT
The European Commission has approved Gilead's (GILD) Zydelig for the treatment of CLL and FL.




Scroll down for more posts ▼

Top 10 Most Recent News Articles

LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 81

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 70

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 199

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 66

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 150

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 108

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 87

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading

Top 5 Most Recently Viewed Articles

Japan's Economic Outlook Dims as Export Weakness Persists

Updated Category News Views 189

Japan's Revised Economic Growth Forecast Recently, Japan's government announced a downward revision of its GDP growth forecast for the current fiscal year. This adjustment is significant as it reflects the ongoing struggles within the economy, particularly in light of weaker export performance that is hindering a fragile recovery. Details on the Growth Projection The...

Continue Reading
The Importance of Employee Recognition in the Workplace

Updated Category News Views 254

The Importance of Employee Recognition in the Workplace Gratitude is a key theme during Thanksgiving, but in the workplace, recognition for employee contributions plays an equally significant role throughout the year. As companies strive to enhance their workplace culture, the value of recognizing employees cannot be overstated. Understanding Employer Perspectives A...

Continue Reading
Class Action Alert for Shareholders of Orthofix Medical

Updated Category News Views 196

Class Action Lawsuit Overview In the current landscape of securities litigation, investors in Orthofix Medical, Inc. have a critical opportunity to engage with a class action lawsuit that addresses significant issues of corporate governance and transparency. This legal action has arisen following severe corporate management changes that have caused share price...

Continue Reading
Understanding Recent Trends in Lowe's Short Interest

Updated Category News Views 107

Understanding Lowe's Companies' Short Interest Lowe's Companies (NYSE: LOW) has seen its short percent of float decrease by 12.78% since the last report. Currently, there are approximately 6.55 million shares sold short, which constitutes 1.16% of all shares available for trading. Given the current trading volume, it would take traders about 2.91 days to cover their short...

Continue Reading
YD Bio Limited and EG Biomed Enhance Clinical Testing with CAP Accreditation

Updated Category News Views 151

Transformative Advancements in Clinical Testing by YD Bio Limited YD Bio Limited, a pioneering biotechnology company known for its advancements in DNA methylation-based cancer detection, recently celebrated a significant milestone through its collaboration with EG Biomed US Inc. This partnership has propelled forward the capabilities of clinical testing, particularly in...

Continue Reading